{"id":"placebo-coated-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Placebo response (symptom improvement without active drug)"},{"rate":null,"effect":"Nocebo response (adverse events attributed to inert tablet)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo tablets are inert formulations used as control comparators in clinical trials to distinguish true drug efficacy from placebo response. They may produce measurable clinical improvements through psychobiological mechanisms including expectation, conditioning, and activation of endogenous healing pathways. In Phase 3 trials, placebos establish the baseline therapeutic effect against which investigational drugs are evaluated.","oneSentence":"Placebo coated tablets contain no active pharmaceutical ingredient and work through the placebo effect, where the expectation of treatment produces therapeutic benefit independent of pharmacological action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:46.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control comparator (non-therapeutic use)"}]},"trialDetails":[{"nctId":"NCT07149649","phase":"PHASE2, PHASE3","title":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-07","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer","enrollment":230},{"nctId":"NCT07497087","phase":"PHASE3","title":"A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-06-09","conditions":"Systemic Sclerosis","enrollment":448},{"nctId":"NCT06031844","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-16","conditions":"Coronary Heart Disease","enrollment":24},{"nctId":"NCT06939296","phase":"PHASE3","title":"A Research Study of VCT220 in Adult Chinese Participants With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2024-12-24","conditions":"Obesity, Overweight","enrollment":840},{"nctId":"NCT05942911","phase":"PHASE2","title":"Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Incannex Healthcare Ltd","startDate":"2023-11-22","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT07225504","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-11","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":1275},{"nctId":"NCT07201129","phase":"PHASE3","title":"A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment","status":"RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2026-02-09","conditions":"Nephritis, Lupus, Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT04472598","phase":"PHASE3","title":"Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-09-29","conditions":"Myelofibrosis (MF)","enrollment":252},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06667700","phase":"PHASE3","title":"A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-02","conditions":"Coronavirus Disease (COVID-19)","enrollment":3082},{"nctId":"NCT07482085","phase":"PHASE3","title":"Efavirenz for the Treatment of Creutzfeldt-Jakob Disease","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-03","conditions":"Creutzfeldt-Jakob Disease","enrollment":246},{"nctId":"NCT07267559","phase":"PHASE4","title":"Dual Orexin Antagonism and Emotion and Affective Processing Study","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-10-01","conditions":"Learning, Cognitive Functioning, Emotional Processing","enrollment":62},{"nctId":"NCT04526119","phase":"PHASE3","title":"A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zeria Pharmaceutical","startDate":"2021-02-22","conditions":"Functional Dyspepsia","enrollment":55},{"nctId":"NCT07322887","phase":"PHASE2","title":"A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"GEN İlaç ve Sağlık Ürünleri A.Ş.","startDate":"2026-03-02","conditions":"Parkinson's Disease (PD)","enrollment":45},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":"Biochemically Recurrent Prostate Cancer","enrollment":985},{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":"Pulmonary Arterial Hypertension","enrollment":935},{"nctId":"NCT06200467","phase":"PHASE1","title":"A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-13","conditions":"Overweight, Obesity","enrollment":110},{"nctId":"NCT05664477","phase":"PHASE2","title":"PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roberta Brinton","startDate":"2024-01-10","conditions":"Menopause, Cognitive Change, Brain Disorder, Metabolic","enrollment":100},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT06868212","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-11","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":400},{"nctId":"NCT05633810","phase":"PHASE3","title":"COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2022-12-21","conditions":"Diabete Type 2, Cardiovascular Diseases","enrollment":10000},{"nctId":"NCT07454408","phase":"PHASE1, PHASE2","title":"Evaluation of the Outcome of Fecal Microbiota Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2026-03-07","conditions":"Hepatic Encephalopathy, Fecal Microbiota Transplantation, TIPS","enrollment":40},{"nctId":"NCT06685835","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insmed Incorporated","startDate":"2024-12-16","conditions":"Hidradenitis Suppurativa","enrollment":214},{"nctId":"NCT05672576","phase":"PHASE3","title":"A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2023-06-26","conditions":"Lupus Erythematosus, Systemic","enrollment":451},{"nctId":"NCT05648500","phase":"PHASE3","title":"A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2022-12-13","conditions":"Lupus Erythematosus, Systemic","enrollment":420},{"nctId":"NCT06383403","phase":"PHASE3","title":"A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2024-07-09","conditions":"Primary Biliary Cholangitis","enrollment":69},{"nctId":"NCT07387549","phase":"PHASE3","title":"A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis","status":"NOT_YET_RECRUITING","sponsor":"Ipsen","startDate":"2026-04-14","conditions":"Primary Sclerosing Cholangitis","enrollment":350},{"nctId":"NCT06273540","phase":"PHASE1","title":"Phase1, STP7 Cocaine Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Stalicla SA","startDate":"2024-04-15","conditions":"Cocaine Use Disorder","enrollment":21},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":"Prostatic Neoplasms","enrollment":669},{"nctId":"NCT05653219","phase":"PHASE3","title":"A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-02","conditions":"Primary Immune Thrombocytopenia","enrollment":152},{"nctId":"NCT06299826","phase":"PHASE2","title":"A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-06-04","conditions":"Chronic Heart Failure","enrollment":375},{"nctId":"NCT06125951","phase":"PHASE2, PHASE3","title":"Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinogen Medical","startDate":"2024-04-12","conditions":"Dementia Moderate, Dementia, Mild, Alzheimer Disease","enrollment":247},{"nctId":"NCT04589650","phase":"PHASE2","title":"Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-19","conditions":"PIK3CA-related Overgrowth Spectrum (PROS)","enrollment":206},{"nctId":"NCT07411482","phase":"NA","title":"The Effect of Probiotic Supplementation on the Exercise Performance of Long-distance Runners.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2023-12-01","conditions":"Intestinal Microbiome, Probiotic, Runners","enrollment":27},{"nctId":"NCT07205250","phase":"EARLY_PHASE1","title":"Aspirin for Prevention of Stroke After Endovascular Aortic Arch Repair: a Multicenter, Double-Blind, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"The General Hospital of Western Theater Command","startDate":"2026-02-20","conditions":"Type B or Non-A Non-B Aortic Dissection;Thoracic Aortic Aneurysm","enrollment":224},{"nctId":"NCT06024421","phase":"PHASE1","title":"Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2024-05-14","conditions":"Infectious Disease, Pharmacology","enrollment":39},{"nctId":"NCT04930549","phase":"PHASE2","title":"Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2022-10-18","conditions":"Renal Insufficiency, Chronic","enrollment":32},{"nctId":"NCT06195072","phase":"PHASE2","title":"Platform Clinical Study for Conquering Scleroderma","status":"RECRUITING","sponsor":"Scleroderma Research Foundation, Inc.","startDate":"2024-04-15","conditions":"Interstitial Lung Disease Due to Systemic Disease, Scleroderma","enrollment":400},{"nctId":"NCT05611931","phase":"PHASE3","title":"Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2023-04-18","conditions":"Endometrial Cancer","enrollment":276},{"nctId":"NCT05834738","phase":"PHASE2","title":"Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-20","conditions":"IgA Nephropathy, Immunoglobulin A Nephropathy","enrollment":54},{"nctId":"NCT03732820","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-31","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":895},{"nctId":"NCT05697640","phase":"PHASE2","title":"Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2023-06-22","conditions":"Post-COVID ME/CFS","enrollment":104},{"nctId":"NCT05540327","phase":"PHASE2","title":"The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-09-16","conditions":"Systemic Lupus Erythematosus","enrollment":379},{"nctId":"NCT05230758","phase":"PHASE3","title":"Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour","status":"RECRUITING","sponsor":"Donald Mabbott","startDate":"2022-07-01","conditions":"Medulloblastoma, Childhood, Cognitive Impairment","enrollment":140},{"nctId":"NCT04576949","phase":"PHASE3","title":"A Study of Cytisinicline for Smoking Cessation in Adult Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2020-10-13","conditions":"Smoking Cessation","enrollment":810},{"nctId":"NCT05431387","phase":"PHASE2","title":"A Study of Cytisinicline for Vaping Cessation in Adult Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2022-07-13","conditions":"Vaping, E-Cig Use","enrollment":160},{"nctId":"NCT05206370","phase":"PHASE3","title":"A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2022-01-20","conditions":"Smoking Cessation","enrollment":792},{"nctId":"NCT06274489","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Setanaxib in Patients With Alport Syndrome","status":"COMPLETED","sponsor":"Calliditas Therapeutics AB","startDate":"2023-11-27","conditions":"Alport Syndrome","enrollment":20},{"nctId":"NCT06579105","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-08","conditions":"Diabetes Mellitus, Type 2","enrollment":406},{"nctId":"NCT07332273","phase":"PHASE3","title":"Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2025-11-05","conditions":"Obesity","enrollment":286},{"nctId":"NCT05321082","phase":"PHASE3","title":"A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-11-16","conditions":"Lung Diseases, Interstitial","enrollment":1178},{"nctId":"NCT04458051","phase":"PHASE3","title":"Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-08-13","conditions":"Primary Progressive Multiple Sclerosis","enrollment":767},{"nctId":"NCT07324434","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects","status":"ENROLLING_BY_INVITATION","sponsor":"Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.","startDate":"2025-12-15","conditions":"Hyperuricemia With or Without Gout","enrollment":69},{"nctId":"NCT07182890","phase":"PHASE4","title":"Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2025-09-20","conditions":"Functional Dyspepsia, Probiotics, Depression","enrollment":180},{"nctId":"NCT07187492","phase":"PHASE4","title":"Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2025-09-20","conditions":"Functional Dyspepsia, Probiotics, Depression","enrollment":180},{"nctId":"NCT02990286","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2017-01-20","conditions":"Lung Disease, Interstitial","enrollment":122},{"nctId":"NCT03630614","phase":"PHASE3","title":"Randomized Trial of Electronic Cigarettes With or Without Nicotine in Smoking Cessation.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-10-17","conditions":"Smoking Cessation, Smoking, Cigarette, Electronic Cigarette","enrollment":650},{"nctId":"NCT03904693","phase":"PHASE3","title":"Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2019-07-29","conditions":"Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","enrollment":187},{"nctId":"NCT06548971","phase":"PHASE3","title":"Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2024-11-07","conditions":"Acute Ischemic Stroke, Cerebral Infarction","enrollment":1184},{"nctId":"NCT07294495","phase":"NA","title":"Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR","status":"NOT_YET_RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2026-01-07","conditions":"HCM - Hypertrophic Cardiomyopathy","enrollment":150},{"nctId":"NCT05593666","phase":"PHASE2","title":"A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Drugs for Neglected Diseases","startDate":"2022-12-27","conditions":"Primary Visceral Leishmaniasis","enrollment":101},{"nctId":"NCT05637710","phase":"PHASE3","title":"Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-03","conditions":"Allergic Rhinitis","enrollment":""},{"nctId":"NCT06579092","phase":"PHASE2","title":"Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-08","conditions":"Obesity or Overweight","enrollment":310},{"nctId":"NCT04496960","phase":"PHASE1, PHASE2","title":"Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2021-05-18","conditions":"Sjogren's Syndrome","enrollment":23},{"nctId":"NCT07038356","phase":"PHASE3","title":"Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure","status":"RECRUITING","sponsor":"Christian Schulze","startDate":"2025-12-08","conditions":"Acute Decompensated Heart Failure (ADHF)","enrollment":536},{"nctId":"NCT05660850","phase":"PHASE2","title":"A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2023-03-22","conditions":"Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough","enrollment":49},{"nctId":"NCT06205121","phase":"PHASE2","title":"Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis","status":"RECRUITING","sponsor":"Molecure S.A.","startDate":"2024-03-21","conditions":"Pulmonary Sarcoidosis","enrollment":96},{"nctId":"NCT04670666","phase":"PHASE3","title":"Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus","status":"RECRUITING","sponsor":"EMS","startDate":"2024-11-18","conditions":"Type 2 Diabetes Mellitus","enrollment":270},{"nctId":"NCT05028140","phase":"PHASE3","title":"Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus","status":"RECRUITING","sponsor":"EMS","startDate":"2024-10-08","conditions":"Type II Diabetes","enrollment":480},{"nctId":"NCT04602754","phase":"PHASE3","title":"Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.","status":"RECRUITING","sponsor":"EMS","startDate":"2023-12-01","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":228},{"nctId":"NCT07266207","phase":"PHASE1","title":"Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Artivila (Shenzhen) Innovation Center, Ltd","startDate":"2024-12-16","conditions":"Rheumatoid Arthritis (RA)","enrollment":94},{"nctId":"NCT06661993","phase":"NA","title":"Alpha-lipoic Acid in Critically Ill Patients With Sepsis","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2024-10-15","conditions":"Sepsis","enrollment":80},{"nctId":"NCT05162586","phase":"PHASE2","title":"The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-03-31","conditions":"Systemic Lupus Erythematosus","enrollment":456},{"nctId":"NCT06107036","phase":"PHASE1","title":"A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-06","conditions":"Healthy","enrollment":46},{"nctId":"NCT04583462","phase":"PHASE3","title":"Impact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-06-02","conditions":"Type 1 Diabetes, Peripheral Arterial Calcification","enrollment":230},{"nctId":"NCT05264506","phase":"PHASE3","title":"Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2022-02-17","conditions":"Contraception","enrollment":3055},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT06013241","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2023-10-30","conditions":"Chronic Rhinosinusitis Without Nasal Polyps","enrollment":288},{"nctId":"NCT03671330","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Breast Cancer","enrollment":327},{"nctId":"NCT06243835","phase":"PHASE1","title":"A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults","status":"TERMINATED","sponsor":"Lohocla Research Corporation","startDate":"2024-04-21","conditions":"Chronic Pain","enrollment":16},{"nctId":"NCT05321069","phase":"PHASE3","title":"A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-10-06","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":1177},{"nctId":"NCT03083665","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-08-22","conditions":"Partial Seizures With or Without Secondary Generalization, Epilepsy","enrollment":449},{"nctId":"NCT07210528","phase":"PHASE1","title":"Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-06-30","conditions":"Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)","enrollment":48},{"nctId":"NCT06834490","phase":"PHASE3","title":"Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2019-11-05","conditions":"Chronic Cerebral Ischemia","enrollment":318},{"nctId":"NCT03742037","phase":"PHASE2","title":"Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-12-21","conditions":"Systemic Lupus Erythematosus","enrollment":427},{"nctId":"NCT02070744","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2014-03","conditions":"Cystic Fibrosis","enrollment":40},{"nctId":"NCT05118672","phase":"PHASE3","title":"Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2025-03-26","conditions":"Cold, Flu Symptom","enrollment":567},{"nctId":"NCT04052360","phase":"PHASE1","title":"Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2019-08-07","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT06705998","phase":"PHASE1","title":"To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects","status":"RECRUITING","sponsor":"BAR Pharmaceuticals s.r.l.","startDate":"2024-12-04","conditions":"NASH","enrollment":52},{"nctId":"NCT05026177","phase":"PHASE3","title":"Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease","status":"TERMINATED","sponsor":"Cassava Sciences, Inc.","startDate":"2021-11-18","conditions":"Alzheimer Disease","enrollment":1125},{"nctId":"NCT02479204","phase":"PHASE1","title":"Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441","status":"TERMINATED","sponsor":"Viatris Innovation GmbH","startDate":"2015-04-28","conditions":"Healthy Subjects","enrollment":10},{"nctId":"NCT04255277","phase":"PHASE1","title":"To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2020-01-31","conditions":"Healthy Subjects","enrollment":97},{"nctId":"NCT03889639","phase":"PHASE2","title":"Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-29","conditions":"Relapsing Multiple Sclerosis","enrollment":130},{"nctId":"NCT07172139","phase":"NA","title":"Transcranial Magnetic Stimulation and Pharmacologic/Probiotic Interventions for Diarrhea-Predominant IBS","status":"NOT_YET_RECRUITING","sponsor":"Rui Li","startDate":"2025-09","conditions":"IBS (Irritable Bowel Syndrome)","enrollment":140},{"nctId":"NCT07145827","phase":"NA","title":"Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen","status":"COMPLETED","sponsor":"Uruk University","startDate":"2024-01-02","conditions":"Breast Cancer, Endometrial Hyperplasia and Endometrial Cancers","enrollment":60},{"nctId":"NCT05132569","phase":"PHASE3","title":"Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-12-03","conditions":"Myasthenia Gravis","enrollment":6},{"nctId":"NCT06782139","phase":"PHASE4","title":"Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-01-20","conditions":"Obesity and Type 2 Diabetes","enrollment":30},{"nctId":"NCT06854601","phase":"PHASE3","title":"Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2019-07-13","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms","enrollment":333},{"nctId":"NCT07121569","phase":"PHASE4","title":"Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes","status":"COMPLETED","sponsor":"Universitas Sebelas Maret","startDate":"2024-07-06","conditions":"Ischemic Stroke, Acute","enrollment":52},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":"H.Pylori Infection","enrollment":700}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":91,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Placebo coated tablets","genericName":"Placebo coated tablets","companyName":"Bionorica SE","companyId":"bionorica-se","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo coated tablets contain no active pharmaceutical ingredient and work through the placebo effect, where the expectation of treatment produces therapeutic benefit independent of pharmacological action. Used for Clinical trial control comparator (non-therapeutic use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}